Bioton

Bioton is an established, commercial-stage Polish biotech company with a strategic focus on diabetes care, primarily through its flagship biosimilar insulin product, Gensulin. The company has a fully integrated model encompassing R&D, manufacturing, and commercialization, with a significant presence in its home market and international operations. Its business is built on providing affordable, complex therapeutic solutions for diabetes, supported by patient education and digital health initiatives.

End-to-end recombinant DNA platform for biosimilar insulin production, from genetic engineering and microbial fermentation to purification, formulation, and device development.

Bioton competes in the biosimilar and generic insulin market against global pharmaceutical giants (e.g., Novo Nordisk, Sanofi, Eli Lilly) and other biosimilar manufacturers. Competition is primarily on price, quality, and reliability of supply. Its main competitive advantages are vertical integration, deep regional expertise in Central & Eastern Europe, and a focused, patient-centric approach to diabetes care.